GNFT: Strong cash position and IqirvoⓇ-driven revenue support pipeline and long-term funding

Cash and cash equivalents rose to €107.5 million, with a €26.5 million milestone for Iqirvo® boosting liquidity. Revenues fell year-over-year, and a net loss of €10.0 million was reported due to higher R&D and financial charges. Pipeline progress and market dynamics support a positive long-term outlook.

Original document: Genfit SA [GNFT] SEC 6-K Current Report — Sep. 22 2025

Cash and cash equivalents rose to €107.5 million, with a €26.5 million milestone received in July. Revenues fell to €35.7 million in 1H25, and a net loss of €10.0 million was reported due to higher R&D and financial charges. Discontinuation of VS-01 in ACLF extends cash runway beyond 2028.

Original document: Genfit SA [GNFT] Earnings Release — Sep. 22 2025

(11:22 GMT) Genfit Price Target Announced at $9.00/Share by HC Wainwright & Co.

European equities traded in the US as American depositary receipts were tracking higher late Tuesday morning, rising 0.56% to 1,478.37 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk and telecommunications company Nokia , which rose 2.5% and 1.4% respectively. They were followed by medical device maker EDAP TMS and brewing company Anheuser-Busch InBev , which were up 1.3% and 1.2% respectively.

The decliners from continental Europe were led by semiconductor company Sequans Communications and biopharmaceutical company Cellectis , which fell 3.9% and 3.2% respectively. They were followed by biopharmaceutical companies Genfit and Grifols , which lost 2.8% and 1.6% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals and NuCana , which advanced 7% and 4.1% respectively. They were followed by communications company WPP and alcoholic beverage company Diageo , which increased 2.4% and 2.2% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Adaptimmune Therapeutics and Amarin , which dropped 3.5% and 1.7% respectively. They were followed by biotech firm Trinity Biotech and cruise line operator Carnival 1.1% and 0.7%.

European equities traded in the US as American depositary receipts opened the week higher late Monday morning, rising 0.55% to 1,474.68 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by semiconductor company Sequans Communications and 3D printer company Materialise , which rose 4.6% and 2.7%, respectively. They were followed by telecommunications operator Telefonica and financial services company Banco Santander , which were up 1.5% and 1.1%, respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies and internet browser company Opera , which lost 3% and 2.7%, respectively. They were followed by biopharmaceutical company Genfit and medical device maker EDAP TMS , which fell 1.5% and 1.3%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company NuCana and biotech firm Autolus Therapeutics , which advanced 7.8% and 6%, respectively. They were followed by mining company BHP and biopharmaceutical company Bicycle Therapeutics , which increased 3.2% and 2.7%, respectively.

The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics and biotech firm Trinity Biotech , which dropped 3.3% and 3.2%, respectively. They were followed by biopharmaceutical companies Akari Therapeutics and Mereo BioPharma Group , which were down 1% each.